Market capitalization | $4.85m |
Enterprise Value | $-3.35m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.36 |
P/B ratio (TTM) P/B ratio | 0.56 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-11.85m |
Free Cash Flow (TTM) Free Cash Flow | $-9.42m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
2 Analysts have issued a Aethlon Medical, Inc. forecast:
2 Analysts have issued a Aethlon Medical, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.35 -0.35 |
235%
235%
|
|
EBITDA | -11 -11 |
5%
5%
|
EBIT (Operating Income) EBIT | -12 -12 |
4%
4%
|
Net Profit | -12 -12 |
7%
7%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aethlon Medical, Inc. is a therapeutic technology company, which focuses on addressing global health and biodefense needs. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The firm operates through two segments: Aethlon and ESI. The Aethlon segment involves in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in May 1998 and is headquartered in San Diego, CA.
Head office | United States |
CEO | James Frakes |
Employees | 14 |
Founded | 1991 |
Website | www.aethlonmedical.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.